Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBCBS Nebraska REN Coverage Prior Auth Policy | Ope…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NebraskaPolicy I.218

    REMOTE ELECTRICAL NEUROMODULATION FOR MIGRAINES (REQUIRES PREAUTHORIZATION)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy I.218 alerts

    Get alerted when Policy I.218 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines medical necessity, coverage criteria, contraindications, and prior authorization requirements for use of remote electrical neuromodulation devices (e.g., Nerivio) for acute and preventive treatment of migraine for BCBS Nebraska members.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyRemote electrical neuromodulation for migraines (requires preauthorization)
    Policy CodePolicy I.218
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2027
    Next Review DateMay 6, 2027
    Key ActionObtain preauthorization and document age, ICHD-3 diagnosis, 6–24 headache days per 28-day period for each of the prior 3 months, and required prior medication trial information.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6-24 daysheadache days per 28-day period
    18+min age (adult)
    >=8 yrsmin age (pediatric prevention)
    8-12 wksassessment period (preventive)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    A4540HCPCS

    Coverage Criteria for Remote Electrical Neuromodulation (REN)

    Initial Therapy (Adults)

    Initiation of Use — REN is medically necessary when ALL of the following are met:

    Adult initiation criteria

    • Additional criteria (pick one): 1) Insufficient response, contraindication, or intolerance to 2 or more guideline-recommended preventive headache medications (e.g., anticonvulsants, antihypertensives, antidepressants, CGRP inhibitors); OR 2) Pregnancy, breastfeeding, or planning to conceive; OR 3) At risk for or have a history of medication overuse headache; OR 4) At risk for drug-drug interactions with medications for comorbid conditions.

    Initial Therapy (Pediatrics, prevention)

    Preventive treatment — pediatric preventive coverage when ALL of the following are met:

    Pediatric preventive criteria: Individual is 8 to 17 years of age; AND Headaches meet the International Classification of Headache Disorders (ICHD-3) diagnostic criteria for migraine with or without aura; AND The REN device will be used for prevention of migraine in individuals with 6 to 24 headache days per 28-day period in each of the 3 months preceding use.

    Clinical input notes first-line use may be recommended in children/adolescents; reduction in school absenteeism may be used to assess benefit.

    Continuation Therapy

    Continuation of Use — REN continued when ALL of the following are met:

    Continuation criteria: A. Compliance with ongoing use; AND B. Documentation of clinical benefit (examples: improved pain relief/freedom, reduced headache frequency/duration/severity, reduced functional disability, reduced absenteeism, reduction in concomitant headache medications). Assessment after a minimum of 8-12 weeks is reasonable for preventive treatment.

    Clinician attestation is acceptable for documenting benefit.

    Investigational Use

    Investigational/Not covered conditions: Use of REN for prevention and management of migraine outside of the stated criteria is considered investigational.

    Nerivio (remote electrical neuromodulation) is contraindicated in patients with uncontrolled epilepsy and in patients with an active implantable medical device such as a pacemaker, hearing aid implant, or any implanted electronic device. The device has not been evaluated in patients with congestive heart failure, severe cardiac or cerebrovascular disease, pregnancy, or in patients under 8 years of age.

    These Medical Policies have been developed by the BCBSN Medical Policy Committee to guide determination of scientific validity and to assist in administering plan benefits. The policies are evidence-based and subject to change; they do not constitute authorization, certification, or a contract for benefits. Benefits for a particular service or item are determined by the terms and conditions of the applicable benefit contract, and providers remain responsible for delivering medical advice and treatment.

    Use of remote electrical neuromodulation (REN) for prevention or management of migraine that falls outside the policy's specified medical necessity criteria is considered investigational and may be denied. Examples include use in individuals who do not meet the age criteria, those without an ICHD-3 migraine diagnosis, or when the requirement of 6 to 24 headache days per 28-day period in each of the prior 3 months is not met.

    Coding and Key Numeric Criteria

    HCPCS codes listedHCPCS
    A4540Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm
    Referenced codingmixed
    affected codesThe policy references CPT codes; specific codes are listed elsewhere in the full policy.
    Headache day frequency — 6 to 24 headache days per 28-day period in each of the 3 months preceding use
    Required frequency6 to 24 headache days per 28-day period in each of the 3 months preceding use
    Count definition reference periodPer 28-day period, assessed for each of the prior 3 months
    Applicable populationsAdults (initiation) and pediatrics (prevention) when other age criteria met
    Assessment period for preventive benefit — Minimum 8-12 weeks
    Minimum assessment intervalMinimum 8–12 weeks for preventive treatment assessment
    Basis for intervalPivotal study durations and International Headache Society recommendations for neuromodulation trial designs

    Provider Requirements and Prior Authorization

    Prior Authorization

    Preauthorization required — document age, ICHD‑3 diagnosis, headache frequency

    REN (e.g., Nerivio) requires preauthorization. Requests must document medical necessity including that the individual is ≥18 years old, that headaches meet ICHD‑3 diagnostic criteria for migraine, and the frequency of headache days (6 to 24 headache days per 28‑day period in each of the 3 months preceding use).

    • Include age (≥18 years).
    • Confirm ICHD‑3 migraine diagnosis.
    • Provide headache day counts for each of the prior 3 months (6–24 per 28‑day period).
    Prior Authorization

    Preauthorization requirement — submit as specified by BCBS‑NE

    Remote electrical neuromodulation for migraine requires preauthorization as specified by BCBS‑NE; affected billing codes are referenced elsewhere in the policy and must be included with the authorization request as applicable.

    • Follow BCBS‑NE preauthorization procedures and submit any referenced CPT/HCPCS codes (see coding section).

    Background

    Migraine is a common neurologic disorder with episodic and chronic presentations defined by headache frequency. Remote electrical neuromodulation (REN) devices such as Nerivio are nonpharmacologic, wearable stimulators applied to the upper arm that activate peripheral nerves to induce conditioned pain modulation. REN may be used acutely at migraine onset and can also be used every-other-day for preventive treatment. Clinical use aims to reduce headache frequency and severity, improve function (for example, reduce work or school absenteeism), and decrease use of acute headache medications.

    Definitions

    Headache day — definition
    DefinitionA calendar day with headache regardless of severity or duration
    Use in policyUsed to calculate 6–24 headache days per 28-day period in each of the 3 months preceding device use
    Counting guidanceEach calendar day with any headache counts as one headache day for the 28-day period tally
    Remote electrical neuromodulation (REN) — definition and mechanism
    Basic definitionRemote electrical neuromodulation (REN) is a nonpharmacologic device-based therapy (e.g., Nerivio) that stimulates peripheral nerves on the upper arm to induce conditioned pain modulation
    MechanismDevice worn on the upper arm delivers electrical stimulation to peripheral nerves; induced conditioned pain modulation in the arm is believed to reduce perceived migraine pain intensity
    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyRemote electrical neuromodulation for migraines (requires preauthorization)
    Policy CodePolicy I.218
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2027
    Next Review DateMay 6, 2027
    Key ActionObtain preauthorization and document age, ICHD-3 diagnosis, 6–24 headache days per 28-day period for each of the prior 3 months, and required prior medication trial information.
    SourceLink
    On This Page
    Coverage Criteria for Remote Electrical Neuromodulation (REN)Coding and Key Numeric CriteriaProvider Requirements and Prior AuthorizationBackgroundDefinitions
    Use for continuation decisionsAssess clinical benefit after this period (e.g., reduced frequency/severity/duration, functional improvement)
    Step Therapy

    Required prior medication trials (adults) — document ≥2 guideline preventive trials

    For adult initiation, include documentation of insufficient response, contraindication, or intolerance to two or more guideline‑recommended preventive headache medications as one pathway to meet the additional criteria for REN.

    • Examples of guideline‑recommended preventive medications: anticonvulsants, antihypertensives, antidepressants, CGRP inhibitors.
    • Provider must state whether trials were inadequate due to lack of efficacy, contraindication, or intolerance.
    Documentation Required

    Provide complete supporting documentation and clinician attestations

    Ensure authorization requests include all required supporting documentation and attestations; clinician attestation of medical necessity and prior treatment history should be provided where applicable.

    • Include prior treatment history and reason for REN consideration (e.g., pregnancy, medication overuse risk, drug‑drug interaction risk).
    • Provide clinician attestation when documenting clinical benefit for continuation requests.
    Documentation Required

    Required documentation — age, ICHD‑3 confirmation, headache day counts

    Required documentation for both initiation and continuation must include the patient’s age, confirmation that headaches meet ICHD‑3 diagnostic criteria, and the count of headache days per 28‑day period for each of the prior 3 months.

    • For continuation, also document clinical benefit (examples: improved pain relief, reduced frequency/severity/duration, reduced functional disability, reduced absenteeism, or reduced concomitant medication use).
    • Assessment for preventive benefit is reasonable after a minimum of 8–12 weeks.
    Note

    Committee reviews scientific publications to develop evidence‑based policies

    The BCBS‑NE Medical Policy Committee reviews scientific publications to develop evidence‑based policies; providers should recognize policies are based on those reviews and continue to provide individualized medical care.

    • The Committee reviews peer‑reviewed journals and new technologies on a regular basis to inform policies.
    Denial Risk

    Coverage outside criteria is investigational — risk of denial

    Use of REN outside the specified medical necessity criteria (age, ICHD‑3 migraine diagnosis, 6–24 headache days per 28‑day period in each of the prior 3 months, or the listed additional indications) is considered investigational and may be denied.

    • Do not request coverage for indications outside the policy criteria without supporting evidence; such requests are subject to denial.
    Note

    Policy administrative disclaimer — policies used to administer benefits, not a benefit guarantee

    These Medical Policies are used to administer plan benefits and do not constitute authorization, certification, or a contract for benefits; coverage for a specific service is determined by the member’s benefit contract.

    • Providers remain responsible for providing medical advice and treatment regardless of policy determinations.
    Device control and useDevice is controlled via Bluetooth and a smartphone/tablet app; used at migraine onset for acute treatment or every-other-day for prevention
    REN — Short label definition
    Short labelREN (Remote electrical neuromodulation)
    Synonym/exampleNerivio (example of REN device)
    ContextUsed for acute and preventive migraine treatment per policy